Product Description
NVG-222 is an extended-half-life version of NovalGen’s clinically derisked NVG-111 bispecific T cell engager. Designed with the same ROR1 and CD3 binding arms, NVG-222 comprises our novel, proprietary auto-regulation technology. This breakthrough technology has been smart-designed to inactivate NVG-222 in settings where there is risk of life threatening toxicity without impacting on efficacy. (Sourced from: https://www.novalgen.com/pipeline/)
Mechanisms of Action: ROR1 Antagonist,CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|